Back to top
more

Gilead Sciences (GILD)

(Real Time Quote from BATS)

$74.30 USD

74.30
1,261,827

+0.52 (0.71%)

Updated Aug 19, 2024 01:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth B Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 28% (70 out of 250)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Biotech Stock Roundup: CELG, REGN Present Data, VKTX Soars on Drug's Success

Pipeline updates and data read-outs at the 27th European Academy of Dermatology and Venereology (EADV) Congress in France comprise some of the key developments in the biotech sector this week.

    Viking Therapeutics Liver Candidate Passes Test, Shares Soar

    Viking Therapeutics (VKTX) pipeline candidate, VK2809, achieves statistically significant reduction in liver fat content and bad cholesterol levels in a phase II study, evaluated for NAFLD.

      Dr. Reddy's (RDY) Presence in Generics Market Remains Strong

      Dr. Reddy's has a strong hold in the generics market. New product launches, especially complex generics, are likely to drive the generics business at regular intervals.

        Is Gilead (GILD) a Suitable Stock for Value Investors Now?

        Let's see if Gilead Sciences, Inc. (GILD) stock is a good choice for value-oriented investors right now, or if investors subscribing to this methodology should look elsewhere for top picks.

          Theravance, Mylan Report Positive Data on COPD Drug Yupelri

          Theravance (TBPH) and partner Mylan post positive data from a late-stage program on COPD Drug, Yupelri.

            Agenus Receives Milestone Payment of $5 Million from Incyte

            Agenus (AGEN) receives a milestone payment of $5 million from Incyte on the initiation of a phase I study of INCAGN2385.

              Should Value Investors Pick Gilead Sciences (GILD) Stock?

              Is Gilead Sciences (GILD) a great pick from the value investor's perspective right now? Read on to know more.

                Unity (UBX) Catches Eye: Stock Jumps 8.8%

                Unity (UBX) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.

                  Gilead Inks Gene Editing Collaboration Deal for HBV Infection

                  Gilead (GILD) enters into a strategic collaboration with Precision BioSciences for developing therapies aimed at eliminating hepatitis B virus by using the latter's gene editing platform ARCUS.

                    Company News For Sep 13, 2018

                    Companies in the news are: GILD, VZ, BHC and WBC

                      Gilead's Rheumatoid Arthritis Drug Successful in Phase III

                      Gilead (GILD) and partner Galapagos' rheumatoid arthritis candidate meets all primary and key secondary endpoints in first phase III study.

                        Biotech Stock Roundup: GILD's Arthritis Drug Successful in Phase III, PRQR Soars

                        Pipeline updates and collaborating agreement comprise some of the key developments in the biotech sector this week.

                          Merck's Antibacterial Drug Succeeds in Label Expansion Study

                          Merck's (MRK) label expansion study evaluating its antibacterial drug, Zerbaxa for two types of pneumonia infections meets primary endpoints.

                            Regeneron/Sanofi's sBLA for Praluent to be Reviewed by FDA

                            The FDA will review Regeneron (REGN) and Sanofi's sBLA for its PCSK9 Inhibitor Praluent to reduce risk of major adverse cardiovascular events.

                              Incyte, Foundation Medicine Partner for Companion Diagnostics

                              Incyte (INCY) inks an agreement with Foundation Medicine for the development of companion diagnostics (CDx) for Incy's selective FGFR Inhibitor, pemigatinib.

                                Endocyte Announces FDA's Acceptance of Trial Endpoint Change

                                177Lu-PSMA-617, a prostate specific membrane antigen-targeted radioligand therapy, is Endocyte's (ECYT) lead program. It is being evaluated in a phase III study for mCRPC for PSMA-positive patients

                                  Gilead Sciences (GILD) Outpaces Stock Market Gains: What You Should Know

                                  Gilead Sciences (GILD) closed the most recent trading day at $72.51, moving +0.36% from the previous trading session.

                                    Shire's ADHD Portfolio Remains Strong Amid Competition

                                    Shire (SHPG) has a strong hold in the attention deficit hyperactivity disorder (ADHD) market despite facing competition.

                                      Inovio's Early/Mid-Stage Vaccine Pipeline Exhibits Growth

                                      Inovio (INO) focuses on the development of its most advanced candidate, VGX-3100 vaccine, which has been progressing well. Its collaboration with big pharma companies exhibits strong growth.

                                        The Zacks Analyst Blog Highlights: Abbott, Gilead, FedEx, Archer Daniels and CBRE

                                        The Zacks Analyst Blog Highlights: Abbott, Gilead, FedEx, Archer Daniels and CBRE

                                          Inovio Initiates Dosing in Phase I/IIa Study on MERS Vaccine

                                          Inovio Pharmaceuticals (INO) administers dosage in the first patient under a phase I/IIa trial to assess its MERS vaccine INO-4700.

                                            Mark Vickery headshot

                                            Top Research Reports for Abbott, Gilead & FedEx

                                            Today's Research Daily features new research reports on 16 major stocks, including Abbott (ABT), Gilead (GILD) and FedEx (FDX).

                                              bluebird (BLUE) Reports Updated Data on Lenti-D Gene Therapy

                                              bluebird bio (BLUE) announces updated results from phase II/III Starbeam study of its Lenti-D gene therapy in boys aged 17 years or below with CALD.

                                                Gilead, Galapagos Spondylitis Drug Meets Primary Endpoint

                                                Gilead's (GILD) ankylosing spondylitis candidate, filgotinib meets primary endpoint in phase II study.

                                                  ProQR Up More Than 120% on Favorable Eye Disorder Study Data

                                                  ProQR Therapeutics (PRQR) presents positive data from a phase I/II study on QR-110, its lead pipeline candidate for LCA 10, the most common genetic cause of visual impairment in kids.